RAB10 and Parkinson disease: There were no significant differences in pT73-Rab10 levels amongst control, LRRK2 mutation PD, LRRK2 NMC and idiopathic PD samples, even though pT73-Rab10 levels were susceptible to MLi2 treatment in most cases (Fig. 5c, Supplementary Figs. 9–10).